Navigation Links
Luminex Corporation to Present at JP Morgan Healthcare Conference
Date:1/4/2012

AUSTIN, Texas, Jan. 4, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that management will present at the 30th Annual JP Morgan Healthcare Conference to be held January 9 -12, 2012, in San Francisco, CA.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

The investor presentation by Patrick J. Balthrop, president and chief executive officer, will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Wednesday, January 11, 2012.  The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived for six months on the website using the 'replay' link.

ABOUT LUMINEX CORPORATION Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com.Contacts:

Harriss T. Currie 

Chief Financial Officer 

Vice President Finance 

512-219-8020 

  

Matthew Scalo 

Sr. Director of Investor Relations 

512-219-8020 

mscalo@luminexcorp.com 

  


'/>"/>

SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Luminex Corporation Joins Forces With the National Marrow Donor Program - Be The Match®
2. Neogen Corporation Announces 2nd Quarter Results Conference Call
3. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
4. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
5. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
6. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
7. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
8. China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 19, 2011
9. China Cord Blood Corporation Files Its Annual Report on Form 20-F
10. McKesson Corporation Unveils New Offerings to Empower the Community Patient Care Delivery System
11. Spectros Corporation Signs Distribution Agreements in Korea, Switzerland, Denmark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 2017  Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, announced ... showed that aerosolized KL4 surfactant reduced lung inflammation ... animal model. The Company believes that these preclinical ... that supports the role of KL4 surfactant as ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 /PRNewswire/ ... their $7M Series B financing, adding an additional $3M ... led by Mesa Verde Venture Partners and other strategic ... be directed towards further accelerating commercial adoption of their ... profiling test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... ... February 15, 2017 , ... Executive search firm, ... Officer with GenePeeks. Matt is a veteran life sciences and molecular diagnostics ... company focused on identifying inherited disease risk in future generations. In his new ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. („TRIANNI") ... Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung der ... führenden Plattform für die Entdeckung monoklonaler Antikörper. ... neuartiges chimäres Gensegmentdesign aus, das Janssen den ... Antikörpern bietet und das für die schelle Isolierung ...
Breaking Biology Technology:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/8/2017)... Feb. 8, 2017 About Voice Recognition Biometrics ... match it against a stored voiceprint template. Acoustic ... cadence, and tone are compared to distinguish between ... installation, as most PCs already have a microphone ... Voice recognition biometrics are most likely to be ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
Breaking Biology News(10 mins):